At a time when most US gene editing companies have trimmed their pipelines, China-based YolTech Tx has brought six CRISPR therapies into the clinic. Now they've raised $70M to ramp up trials in China and the US. Read more in my exclusive for @endpts.com: endpoints.news/china-gene-e...
Exclusive: China gene editing startup YolTech raises $70M to move CRISPR therapies forward
Yoltech Therapeutics, one of China’s most prolific gene editing companies has raised its biggest round of funding ahead of plans to go public in Hong Kong.
endpoints.news
May 28, 2026 at 1:55 PM
At a time when most US gene editing companies have trimmed their pipelines, China-based YolTech Tx has brought six CRISPR therapies into the clinic. Now they've raised $70M to ramp up trials in China and the US. Read more in my exclusive for @endpts.com: endpoints.news/china-gene-e...
YOLT-101
Another single-infusion #BaseEditor therapy for Heterozygous Familial Hypercholesterolemia
From #YolTech Therapeutics
0.6 mg/kg N=3
Being effective in 1 wk
Sustained 70% ⬇️plasma PCSk9 & 50% ⬇️LDL-C till 16-wk
medRxiv 2025
www.medrxiv.org/content/10.1...
Another single-infusion #BaseEditor therapy for Heterozygous Familial Hypercholesterolemia
From #YolTech Therapeutics
0.6 mg/kg N=3
Being effective in 1 wk
Sustained 70% ⬇️plasma PCSk9 & 50% ⬇️LDL-C till 16-wk
medRxiv 2025
www.medrxiv.org/content/10.1...
November 11, 2025 at 8:04 PM
YOLT-101
Another single-infusion #BaseEditor therapy for Heterozygous Familial Hypercholesterolemia
From #YolTech Therapeutics
0.6 mg/kg N=3
Being effective in 1 wk
Sustained 70% ⬇️plasma PCSk9 & 50% ⬇️LDL-C till 16-wk
medRxiv 2025
www.medrxiv.org/content/10.1...
Another single-infusion #BaseEditor therapy for Heterozygous Familial Hypercholesterolemia
From #YolTech Therapeutics
0.6 mg/kg N=3
Being effective in 1 wk
Sustained 70% ⬇️plasma PCSk9 & 50% ⬇️LDL-C till 16-wk
medRxiv 2025
www.medrxiv.org/content/10.1...
YolTech raised $45M to advance its CRISPR therapies, aiming for its first Phase 3 trial at a time when US rivals are scaling back and investors are eyeing China’s biotech scene.
Exclusive: Chinese CRISPR company YolTech raises $45M as it plans for first Phase 3 study
YolTech Therapeutics raises $44.5M Series B for CRISPR therapies, led by AstraZeneca-CICC fund. Company has 4 therapies in clinical trials, plans Phase 3 for ATTR treatment.
endpoints.news
September 10, 2025 at 8:51 PM
YolTech raised $45M to advance its CRISPR therapies, aiming for its first Phase 3 trial at a time when US rivals are scaling back and investors are eyeing China’s biotech scene.
YolTech Therapeutics becomes the latest Chinese company to get ahead of the US with a clinical trial of an experimental CRISPR therapy.
endpts.com/chinese-star...
endpts.com/chinese-star...
Chinese startup begins first trial of in vivo CRISPR therapy for blood disease
A little-known Chinese biotech startup has zipped ahead of US companies in one of the gene editing field’s most competitive races.
endpts.com
January 23, 2025 at 3:49 PM
YolTech Therapeutics becomes the latest Chinese company to get ahead of the US with a clinical trial of an experimental CRISPR therapy.
endpts.com/chinese-star...
endpts.com/chinese-star...
YolTech Therapeutics Secures $45 Million in Series B Funding to Advance Gene-Editing Therapies#China#Shanghai#YolTech_Therapeutics#gene-editing#AstraZeneca-CICC
YolTech Therapeutics Secures $45 Million in Series B Funding to Advance Gene-Editing Therapies
YolTech Therapeutics has successfully raised $45 million in Series B funding, led by AstraZeneca-CICC, to progress its innovative gene-editing therapies.
third-news.com
September 11, 2025 at 12:27 PM
YolTech Therapeutics Secures $45 Million in Series B Funding to Advance Gene-Editing Therapies#China#Shanghai#YolTech_Therapeutics#gene-editing#AstraZeneca-CICC
Chinese #CRISPR company YolTech Therapeutics has raised a $45M series B as it plans for its first Phase 3 study in ATTR, the same genetic disease that US-based Intellia recently began a pair of Phase 3 studies in. Read more in my exclusive for
@endpts.com: endpoints.news/chinese-cris...
@endpts.com: endpoints.news/chinese-cris...
Exclusive: Chinese CRISPR company YolTech raises $45M as it plans for first Phase 3 study
YolTech Therapeutics raises $44.5M Series B for CRISPR therapies, led by AstraZeneca-CICC fund. Company has 4 therapies in clinical trials, plans Phase 3 for ATTR treatment.
endpoints.news
September 10, 2025 at 3:33 PM
Chinese #CRISPR company YolTech Therapeutics has raised a $45M series B as it plans for its first Phase 3 study in ATTR, the same genetic disease that US-based Intellia recently began a pair of Phase 3 studies in. Read more in my exclusive for
@endpts.com: endpoints.news/chinese-cris...
@endpts.com: endpoints.news/chinese-cris...
[1/2] 2026-07-20 09:31:38 - [YolTech Therapeutics announced the appointment of Yang Zhiyun as Chief Financial Officer] On July 20, YolTech Therapeutics announced the appointment of Jessie Yeung as Chief Financial Officer (CFO). Yang Zhiyun will lead the financial strategy to
July 20, 2026 at 1:40 AM
[1/2] 2026-07-20 09:31:38 - [YolTech Therapeutics announced the appointment of Yang Zhiyun as Chief Financial Officer] On July 20, YolTech Therapeutics announced the appointment of Jessie Yeung as Chief Financial Officer (CFO). Yang Zhiyun will lead the financial strategy to
[1/2] 2026-05-29 09:34:05 - [YolTech Therapeutics completed nearly 500 million yuan in Series C financing] On May 29, YolTech Therapeutics announced the completion of nearly 500 million yuan in Series C financing. This round of financing was led by Zhengxingu Capital, and well-known
May 29, 2026 at 1:42 AM
[1/2] 2026-05-29 09:34:05 - [YolTech Therapeutics completed nearly 500 million yuan in Series C financing] On May 29, YolTech Therapeutics announced the completion of nearly 500 million yuan in Series C financing. This round of financing was led by Zhengxingu Capital, and well-known
#YolTech announcement today forces me to address #China biotech competition (blog): rnaitherapeutics.blogspot.com/2025/04/chin...
$VERV #CRISPR
$VERV #CRISPR
China Fast-Follower Competition Reaches Clinical CRISPR
There is panic among Western biotech that Chinese competitors will eat their lunch with their capital-efficient fast-follower strategy which...
rnaitherapeutics.blogspot.com
April 28, 2025 at 3:26 PM
#YolTech announcement today forces me to address #China biotech competition (blog): rnaitherapeutics.blogspot.com/2025/04/chin...
$VERV #CRISPR
$VERV #CRISPR
#Yoltech with #China investigator-initiated n=6 #PCSK9 base editor data.
Very similar approach to $verv, sees 50%LDLc lowering, but 50% with 'mild' liver enzme elevations.
www.prnewswire.com/news-release...
Very similar approach to $verv, sees 50%LDLc lowering, but 50% with 'mild' liver enzme elevations.
www.prnewswire.com/news-release...
YolTech Announces First Clinical Data from Ongoing Investigator-Initiated Trial of YOLT-101, An In-Vivo Base Editing Therapy for Familial Hypercholesterolemia
/PRNewswire/ -- YolTech Therapeutics Co.,Ltd, a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic...
www.prnewswire.com
April 28, 2025 at 12:00 PM
#Yoltech with #China investigator-initiated n=6 #PCSK9 base editor data.
Very similar approach to $verv, sees 50%LDLc lowering, but 50% with 'mild' liver enzme elevations.
www.prnewswire.com/news-release...
Very similar approach to $verv, sees 50%LDLc lowering, but 50% with 'mild' liver enzme elevations.
www.prnewswire.com/news-release...
Alpha-1 Antitrypsin Deficiency used to mean weekly infusions. Now? Early human trial of YolTech's base-editing therapy shows corrected AAT (that's the protein they're missing) in 2 patients. Levels even hit normal! Phase 2/3, fingers crossed.
FDA Clears YolTech's In Vivo Base-Editing Therapy for Alpha-1 Antitrypsin Deficiency, Showing Promis
YolTech has received FDA clearance to advance its in vivo adenine base-editing therapy, YOLT-202, into a Phase 2/3 clinical trial for adults with alpha-1 antitrypsin deficiency (AAT). Early results fr
crisprmedicinenews.com
March 21, 2026 at 2:05 AM
Alpha-1 Antitrypsin Deficiency used to mean weekly infusions. Now? Early human trial of YolTech's base-editing therapy shows corrected AAT (that's the protein they're missing) in 2 patients. Levels even hit normal! Phase 2/3, fingers crossed.
Feed: "Clinical Trials Arena"
By: Salong Debbarma on Monday, March 16, 2026
By: Salong Debbarma on Monday, March 16, 2026
YolTech Therapeutics gains FDA approval for Phase II/III AATD trial
YolTech Therapeutics has received clearance from the US FDA to begin a Phase II/III clinical study of its in vivo gene-editing therapy, YOLT-202, for AATD.
www.clinicaltrialsarena.com
March 16, 2026 at 4:20 PM
Feed: "Clinical Trials Arena"
By: Salong Debbarma on Monday, March 16, 2026
By: Salong Debbarma on Monday, March 16, 2026
Feed: "Business-News-Today.com"
By: Srinath on Sunday, March 15, 2026
By: Srinath on Sunday, March 15, 2026
Why YolTech Therapeutics believes YOLT-202 could become a “one-and-done” treatment for Alpha-1 Antitrypsin Deficiency
YolTech Therapeutics receives FDA clearance to launch a Phase 2/3 trial of YOLT-202 for Alpha-1 Antitrypsin Deficiency. Discover what this means for gene editing.
business-news-today.com
March 15, 2026 at 12:38 AM
Feed: "Business-News-Today.com"
By: Srinath on Sunday, March 15, 2026
By: Srinath on Sunday, March 15, 2026
Feed: "Endpoints News"
By: Ryan Cross on Wednesday, September 10, 2025
By: Ryan Cross on Wednesday, September 10, 2025
Chinese CRISPR company YolTech raises $45M as it plans for first Phase 3 study
YolTech Therapeutics raises $44.5M Series B for CRISPR therapies, led by AstraZeneca-CICC fund. Company has 4 therapies in clinical trials, plans Phase 3 for ATTR treatment.
endpoints.news
September 11, 2025 at 11:41 AM
Feed: "Endpoints News"
By: Ryan Cross on Wednesday, September 10, 2025
By: Ryan Cross on Wednesday, September 10, 2025
Exclusive: Chinese gene editing startup YolTech has raised $70M in Series C funding to advance six CRISPR therapies, as it eyes trials in the US and a Hong Kong IPO.
Exclusive: China gene editing startup YolTech raises $70M to move CRISPR therapies forward
Yoltech Therapeutics, one of China’s most prolific gene editing companies has raised its biggest round of funding ahead of plans to go public in Hong Kong.
endpoints.news
May 28, 2026 at 6:52 PM
Exclusive: Chinese gene editing startup YolTech has raised $70M in Series C funding to advance six CRISPR therapies, as it eyes trials in the US and a Hong Kong IPO.
YolTech Therapeutics Achieves FDA Clearance for Revolutionary Gene-Editing Therapy YOLT-101#Shanghai#None#Gene_Editing#YolTech#YOLT-101
YolTech Therapeutics Achieves FDA Clearance for Revolutionary Gene-Editing Therapy YOLT-101
YolTech Therapeutics has received FDA approval for YOLT-101, a groundbreaking gene-editing therapy aimed at treating familial hypercholesterolemia, marking a pivotal moment in biotechnology.
third-news.com
June 6, 2025 at 3:56 AM
YolTech Therapeutics Achieves FDA Clearance for Revolutionary Gene-Editing Therapy YOLT-101#Shanghai#None#Gene_Editing#YolTech#YOLT-101
YolTech's YOLT-101 Offers Hope for Familial Hypercholesterolemia Patients with Novel Therapy#China#Shanghai#YolTech#YOL-101#Familial_Hypercholesterolemia
YolTech's YOLT-101 Offers Hope for Familial Hypercholesterolemia Patients with Novel Therapy
YolTech Therapeutics reveals positive interim findings from a trial on YOLT-101, an innovative treatment for familial hypercholesterolemia that significantly lowers cholesterol levels.
third-news.com
April 28, 2025 at 5:28 AM
YolTech's YOLT-101 Offers Hope for Familial Hypercholesterolemia Patients with Novel Therapy#China#Shanghai#YolTech#YOL-101#Familial_Hypercholesterolemia
YolTech Therapeutics Unveils Promising Results for YOLT-203, Targeting Primary Hyperoxaluria Type 1#China#Shanghai#YOLT-203#YolTech_Therapeutics#PH1
YolTech Therapeutics Unveils Promising Results for YOLT-203, Targeting Primary Hyperoxaluria Type 1
YolTech Therapeutics shares encouraging data on YOLT-203, an innovative gene-editing treatment for Primary Hyperoxaluria Type 1, showcasing safety and efficacy.
third-news.com
February 25, 2025 at 8:20 AM
YolTech Therapeutics Unveils Promising Results for YOLT-203, Targeting Primary Hyperoxaluria Type 1#China#Shanghai#YOLT-203#YolTech_Therapeutics#PH1
YolTech Therapeutics Launches Exciting Gene Editing Clinical Trial for β-Thalassemia#China#Shanghai#YolTech_Therapeutics#YOLT-204#β-Thalassemia
YolTech Therapeutics Launches Exciting Gene Editing Clinical Trial for β-Thalassemia
YolTech Therapeutics embarks on a significant clinical trial for YOLT-204, an innovative gene therapy targeting β-thalassemia, aiming for curative outcomes.
third-news.com
January 21, 2025 at 2:38 AM
YolTech Therapeutics Launches Exciting Gene Editing Clinical Trial for β-Thalassemia#China#Shanghai#YolTech_Therapeutics#YOLT-204#β-Thalassemia
YolTech Therapeutics Receives FDA Orphan Drug Designations for Innovative Gene Therapy YOLT-203#China#Shanghai#FDA_Approval#YolTech#YOLT-203
YolTech Therapeutics Receives FDA Orphan Drug Designations for Innovative Gene Therapy YOLT-203
YolTech Therapeutics has achieved significant FDA designations for its gene therapy YOLT-203, aimed at treating primary hyperoxaluria type 1, promising hope for affected patients.
third-news.com
December 27, 2024 at 3:20 PM
YolTech Therapeutics Receives FDA Orphan Drug Designations for Innovative Gene Therapy YOLT-203#China#Shanghai#FDA_Approval#YolTech#YOLT-203
YolTech Therapeutics Advances Phase I Trial of YOLT-201 for ATTR with Successful Dose Escalation Results#China#Shanghai#YOLTx#CRISPR#ATTR
YolTech Therapeutics Advances Phase I Trial of YOLT-201 for ATTR with Successful Dose Escalation Results
YolTech Therapeutics has successfully completed the dose escalation phase in its Phase I/IIa trial for YOLT-201, a groundbreaking CRISPR/Cas9 gene-editing treatment for ATTR amyloidosis.
third-news.com
December 21, 2024 at 8:29 AM
YolTech earns FDA IND clearance for YOLT-101—its breakthrough gene-editing therapy for familial hypercholesterolemia.
A milestone in next-gen treatments.
Read More: https://tinyurl.com/ec3pjf43
#genetherapy #ittechpulse #bestplacetowork
A milestone in next-gen treatments.
Read More: https://tinyurl.com/ec3pjf43
#genetherapy #ittechpulse #bestplacetowork
June 6, 2025 at 4:08 PM
YolTech earns FDA IND clearance for YOLT-101—its breakthrough gene-editing therapy for familial hypercholesterolemia.
A milestone in next-gen treatments.
Read More: https://tinyurl.com/ec3pjf43
#genetherapy #ittechpulse #bestplacetowork
A milestone in next-gen treatments.
Read More: https://tinyurl.com/ec3pjf43
#genetherapy #ittechpulse #bestplacetowork
ICYMI: @YolTech Therapeutics announced positive interim data from an investigator-initiated trial of YOLT-202, the Company’s investigational in vivo base editing therapy, for the treatment of alpha-1 antitrypsin deficiency.
Learn more: www.hcplive.com/view...
Learn more: www.hcplive.com/view...
February 20, 2026 at 11:00 AM
ICYMI: @YolTech Therapeutics announced positive interim data from an investigator-initiated trial of YOLT-202, the Company’s investigational in vivo base editing therapy, for the treatment of alpha-1 antitrypsin deficiency.
Learn more: www.hcplive.com/view...
Learn more: www.hcplive.com/view...
